in this issue
Regions :: North America :: U.S.
Lonza Signs Manufacturing Deal with Femta Pharmaceuticals
10:22 PM MST | December 15, 2009 | Deepti Ramesh
Lonza says it has signed a manufacturing services agreement with Femta Pharmaceuticals (San Diego, CA), to facilitate the development and manufacturing of FM101, a high affinity monoclonal antibody in late pre-clinical development for the treatment of rheumatoid arthritis. The agreement gives Femta access to Lonza’s GS Gene Expression System along with cell line, purification and process development to support a cGMP process for Femta’s clinical development program. “By leveraging Lonza’s considerable expertise in gene expression and...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee